Mechanisms of Probiotic VSL#3 in a Rat Model of Visceral Hypersensitivity Involves the Mast Cell-PAR2-TRPV1 Pathway
Mast cells (MCs), PAR2 and TRPV1, play a key role in the regulation of visceral pain. Several studies have found that probiotics regulate visceral sensitivity.
The purpose of the current study was to explore the role of MC-PAR2-TRPV1 in VH and the mechanism of VSL#3 in a rat model of VH.
A total of 64 rats were randomly divided into eight groups: Control VH, VH + ketotifen, VH + FSLLRY-NH2, VH + SB366791, VH + VSL#3, VH + VSL#3 + capsaicin, and VH + VSL#3 + SLIGRL-NH2. The rat model of VH was induced by acetic acid enema and the partial limb restraint method. VH was assessed by the abdominal withdrawal reflex score. MCs in colonic tissue were detected by the toluidine blue staining assay. The expression of PAR2 and TRPV1 in DRGs (L6–S1) was measured by immunohistochemistry and Western blotting.
The established VH was abolished by treatment with ketotifen, a mast cell stabilizer FSLLRY-NH2, a PAR2 antagonist SB366791 a TRPV1 antagonist, and probiotic VSL#3 in rats. The administration of ketotifen or probiotic VSL#3 caused a decrease in mast cell number in the colon and decreased PAR2 and TRPV1 expression in DRGs. Intrathecal injection of FSLLRY-NH2 or SB366791 caused decreased expression of PAR2 and/or TRPV1 in DRGs in VH rats. SLIGRL-NH2, a PAR2 agonist, and capsaicin, a TRPV1 agonist, blocked the effects of probiotic VSL#3.
The probiotic VSL#3 decreases VH in rat model of VH. The mechanism may be related with the mast cell-PAR2-TRPV1 signaling pathway.
KeywordsIrritable bowel syndrome Probiotics VSL#3 Visceral hypersensitivity Mast cells PAR2 TRPV1
This research was supported by the National Nature Science Foundation of China (No. 81300273), the Fund for Scientific Research of The First Hospital of China Medical University (No. FSFH2O1702) and the Liaoning Science and Technology Foundation (No. 20170541052).
Compliance with ethical standards
Conflict of interest
The author declares that they have no conflict of interest.
- 12.Ng SC, Lam FC, Lam TY, et al. Sa2057 Probiotic bacteria VSL#3 alter visceral sensitivity and mucosa-associated intestinal microbiota in patients with irritable bowel syndrome. Gastroenterology. 2012;142:S-391-S-391.Google Scholar
- 13.Boer WD, Otten MH, Man WK, Hing A. Sa2070 VSL#3®, a probiotic combination, reduces the severity of abdominal pain and bloating and improves quality of life in irritable bowel syndrome (IBS): Data from a multi-centre, prospective observational study. Gastroenterology. 2012;142:S-394-S-394.Google Scholar
- 34.Winston JH, Xu GY, Sarna SK. Adrenergic stimulation mediates visceral hypersensitivity to colorectal distension following heterotypic chronic stress. Gastroenterology.. 2010;138(294–304):e293.Google Scholar
- 39.Liu H, Miller DV, Lourenssen S, Wells RW, Blennerhassett MG, Paterson WG. Proteinase-activated receptor-2 activation evokes oesophageal longitudinal smooth muscle contraction via a capsaicin-sensitive and neurokinin-2 receptor-dependent pathway. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2010;22:210–216, e267.CrossRefGoogle Scholar
- 44.Yilmaz Z, Renton T, Yiangou Y, et al. Burning mouth syndrome as a trigeminal small fibre neuropathy: Increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score. J Clin Neurosci Off J Neurosurg Soc Australas. 2007;14:864–871.Google Scholar